T1	Participants 372 429	first-line treatment of metastatic breast carcinoma (MBC)
T2	Participants 439 524	Two hundred twenty-four patients with MBC and no prior therapy for metastatic disease
T3	Participants 1077 1320	Patients were removed from study if LVEF declined 20 or more EF units from baseline to a final value of greater than or equal to 50%, or by 10 or more units to a final value of less than 50%, or onset of clinical congestive heart failure (CHF)
T4	Participants 1330 1378	Median age was 54 years in both treatment groups
